|
 The company did not cite a reason for his departure, but said it was
part of efforts to modify its executive team to focus on "long term
success".
Mark Alles, who became chief executive officer of the drugmaker in
2016, will assume Smith's responsibilities.
The move also makes Alles directly responsible for all major parts
of its business — including clinical development, regulatory and its
lucrative hematology and oncology business — in addition to his
existing duties, the company said.
Smith's departure comes a month after U.S. health regulators, in a
surprise move, rejected Celgene's application seeking approval of a
key multiple sclerosis drug due to insufficient data.
[to top of second column] |
Smith, a longtime employee of the maker of the blockbuster Revlimid
cancer drug, joined in 2008 and served as its president and chief
operating officer since April 2017.
Celgene shares were marginally down in after-market trading.
(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by
Shounak Dasgupta)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
